35 min
New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice touchPODCAST
-
- Science
touchPANEL DISCUSSION for touchONCOLOGY
Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice.
The experts
Prof. Giuseppe Curigliano, University of Milan, Milan, Italy
Prof. Hope Rugo, University of California, San Francisco, CA, USA
Prof. Peter Schmid, Barts Cancer Institute, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc
touchPANEL DISCUSSION for touchONCOLOGY
Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice.
The experts
Prof. Giuseppe Curigliano, University of Milan, Milan, Italy
Prof. Hope Rugo, University of California, San Francisco, CA, USA
Prof. Peter Schmid, Barts Cancer Institute, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc
35 min